Jon’s 25yr career in science and medicine has been built on increasing levels of responsibility in scientific leadership, business development, commercialization and executive management at both early-stage biotech and large multinational biomedical entities including Pharmacia/SUGEN, Rigel, Chiron, Novartis, Ventana, Roche, Expression Pathology and OncoPlex Diagnostics.

In his early career, Jon was in oncology drug development, where he became skilled at driving molecular diagnostics tied to drug development to advance precision medicine and advocate for personalized healthcare.

Most recently Jon was a Managing Partner at Oncology Partners (NYC), a consulting and clinical advisory firm he co-founded, focused on providing strategic counsel to development stage pharma, biotech, medical devices and diagnostic companies.

Previously Jon was president and CEO of OncoPlex Diagnostics, a pioneer in clinical proteomics for oncology. Under his leadership OncoPlex was transformed from a private, pre-revenue stage company into a thriving clinical diagnostics business with marketed products, which was ultimately acquired by NantOmics in May 2015.

Jon received his BSc (Hons) degree in Industrial Chemistry (color) from Leeds University in England. He subsequently completed an MSc. in Physical Chemistry and a Ph.D in Cell & Molecular Biology at the University of Nevada, Reno. Before going into the Pharma Industry, he was a Postdoc and then the Alpha One Foundation Fellow in the lab of Dr David Perlmutter at the Children’s hospital at Washington University in St Louis.

Alexandre read mathematics, physics, chemistry, biochemistry and biophysics at Moscow Institute of Physics and Technology.  In 1989 he was selected by the George Soros Foundation for the Oxford Scholarship, associated with St. Antony’s College, along with 20 top Soviet graduate students from the USSR. He obtained his PhD in cell biology from University College, London (with the research based at the Imperial Cancer Research Fund). He spent six years at the Robert Wood Johnson Medical School-UMDNJ, NJ, as a research assistant funded by the Howard Hughes Medical Institute. Upon his return to England, he established his research laboratory at the Sir William Dunn School of Pathology, University of Oxford.  He was a University Academic Fellow (Research Council UK) and a Senior Fellow of Exeter College, sponsored by Cancer Research UK, the Wellcome Trust, The Medical Research Council and Monsanto Foundation.  Alexandre is also a Fellow of the Royal Society of Medicine.  He is currently a Non-Executive Director of Sibelius Limited.

Aroul read molecular biology and biotechnology at the Indian Agricultural Research Institute, New Delhi, after obtaining National First in the All India Combined Entrance Exam. He was awarded the Felix and Cambridge Commonwealth Scholarships and read bioinformatics at Cambridge University and at the Wellcome Trust Sanger Institute (PhD awarded in 2004). Since then, Aroul worked with Dr. Alexandre Akoulitchev at the Sir William Dunn School of Pathology, Oxford University and is one of the founders of the Company, leading and managing the Oxford BioDynamics laboratory. Aroul developed the key pattern recognition software supporting the Company’s research and is a Fellow of Cambridge Commonwealth Society, Cambridge Philosophical Society and Royal Asiatic Society.

Paul joined the Company in September 2017 from e-Therapeutics plc, where he held the position of Financial Controller from 2012. Paul is a Chartered Accountant and was a Senior Manager at Deloitte, where he worked from 1996 until 2004. Following this, he worked in finance and operations management in the charitable and automotive sectors.  He read Natural Sciences at St John’s College, University of Cambridge.

Ewan’s first degree is in Biochemistry from Edinburgh University, after which he went to Guy’s & St Thomas Medical School, King’s College London to complete his PhD in Statistical Molecular Neurobiology. Since completing, Ewan has worked for several biotechnology vendor companies including Silicon Genetics, Agilent and Thomson Reuters, in business and technical roles. Ewan joined OBD in 2012 and while at OBD he has driven the early Biomarker direction, developed statistical and data pipelines and now he is responsible for leveraging the value of EpiSwitch chromosome conformation data with customers and partners.

Glen has over 20 years of experience in the Biotechnology and Molecular Diagnostics Industries, within both startup and large, multinational corporations. Over the course of his career, Glen has developed significant experience in advancing business growth for companies driven by leading-edge technologies and services within various therapeutic areas. Most recently as Vice President, Corporate Development at HealthTell, Glen developed and led strategic growth initiatives driving the personalized medicine offering to the Pharmaceutical Industry. Previously, he held senior positions at ApoCell, where he was Vice President, Molecular Biomarkers, Beckman Coulter, Genaissance Pharmaceuticals, and Bristol Myers Squibb, amongst others. Glen holds a BS in Biology from the College of Charleston, and an MBA from the University of North Carolina, Greensboro.

Will has over a decade of experience in emerging molecular diagnostic technologies for the Pharmaceutical and Biotechnology industries. Will is responsible for developing strategic collaborations and partnerships with top 50 pharma companies, leading academic and clinical institutes and non-profit foundations. Prior to joining the company, he was one of the founding members of the US team at Genedata and helped establish the commercialization path for a portfolio software product for large molecule R&D. Will started his career was with Selventa, a Cambridge, MA based companion diagnostics company where he led consulting projects with pharma partners to support efforts for patient stratification in clinical trials, identification of molecular subtypes of disease, and construction of network models of disease biology. Will earned a BS in Pharmacological Chemistry and a PhD in Biomedical Science from the University of California, San Diego.

Bartu read Information and Electronic Engineering at Pembroke College, University of Cambridge, obtaining First Class Honours. His fourth year MEng specialization was in Medical Imaging, which he completed with Distinction. Bartu obtained his PhD in Statistical Genetics from the University of Oxford, where he was affiliated to The Queen’s College. He then co- founded a cloud-computing start-up Approxy in California, delivering an exit as CEO after a rapid expansion of the patent portfolio. Subsequently, Bartu joined the founding senior management team of the Cancer Early Detection Advanced Research (CEDAR) Center at the Knight Cancer Institute in OHSU following $1.2bn in philanthropic funding. His role as Commercialization and Innovation Manager was to facilitate CEDAR to become a vibrant innovation hub by managing the IP strategy, leading and negotiating partnerships with many industry and academic collaborators, delivering operational impact, and sitting on CEDAR’s Funding Review Committee to assess early-stage project investments. Bartu is an experienced entrepreneur, IP strategist and technology driver with many patent applications in medical engineering, biologics, computing and graphics.

Jayne read Biomedical Technology and later obtained a PhD in Molecular Biology from the University of Sheffield. She went on to become a Postdoctoral Fellow at the University of Leeds spending 10 years researching nematode resistance in a variety of crops. Subsequently, she moved away from academia into industry to lead the Gene Discovery team at Advanced Technologies Cambridge (a subsidiary of British American Tobacco) researching harm reduction in tobacco. Her next role was as Residue Manager at Oxford Agricultural Trials, working as the Principle Investigator for residue and soil dissipation studies. Jayne joined Oxford BioDynamics as the Laboratory Project Manager in 2015.

Lim read agricultural science with a major in agricultural chemistry from the Kyoto University, Japan, which he followed with a Masters and a PhD from Nara Institute of Science and Technology. His studies had been supported by multiple awards: the Monbusho (Ministry of Education, Sports and Culture, Japan) Scholarship (1989-1996); Sasakawa Fellowship (1996-1999); Young Researcher Fellowship of Nihon Kagaku Shinkokai (Japan Society for the Promotion of Science, JSPS) (1996-1999); and Kanagawa Prefecture Industrial Technology Development Award (2007). He started work at DNA Chip Research Inc. (Yokohama) in 1999 as a Senior Scientist where he was later promoted to R&D Group Manager. Before joining the Company, he was a General Manager at Gene News Diagnostics.

Francis is an enthusiastic post-doctoral Senior Technology Manager, his PhD studies were completed in the Department of Haematology at the Imperial College School of Medicine.

He has spent more than ten years in academic leukaemia research developing genetic tests for the NHS and commercial markets. As a Senior Research Fellow at the University of Southampton he received the Wellcome Trust Postdoctoral Career award. He has 37 peer reviewed papers in the field of molecular genetics and cell biology, and is an international member of the American Society of Hematology.

At Oxford Biodynamics the main focus of his work has been the conversion of the 3C nested PCR  tests to qPCR and the identification of 3C pharmacogenetic lesions. In is his spare time Francis is a ski instructor.

Bipin gained his qualifications as a Chartered Mechanical Engineer, a European Engineer and a Chartered Quality Professional after completing his education at the Middlesex University.
Bipin has acquired extensive experience and knowledge working within Engineering, Manufacturing and Medical Devices Industries in the capacity of an Engineer and a Senior Manager. He spent 10 years in Brazil working for GTE, GE-Black & Decker as a QA Department Manager before returning to the UK.
Bipin has worked in the Netherlands, Germany, France, Sweden, Italy, the USA, Canada and Singapore on multiple quality, regulatory and product development projects on behalf of various companies over the years. Work balance has been divided between full-time and consultancy assignments.
Bipin has developed and implemented quality management systems for Engineering and Medical Devices companies in compliance with the requirements of relevant ISO, FDA, EU standards and regulations. He has qualified as a Lead Auditor for ISO 9001, and an Internal Auditor for ISO 13485/ISO 14971 standards. He actively develops in-house training modules for personnel competency development.

Nadia received a BSc in veterinary medicine from University of Khartoum, and then obtained an MSc (Merit) in Biotechnology from Oxford Brookes University, where work in (The influence of RNA template on the efficiency and sensitivity of reverse transcriptase activity in quantitative PCR).
Nadia joined Oxford BioDynamics as a R &D research technician in 2014, gaining experience and progressing in the company through different roles (RESEARCH SCIENTIST, HTA PD, RA/QA DESIGNEE. In June 2019 appointed as RA/RQ manager and an affiliate of the Research Quality Association.

Mehrnoush read cellular and molecular biology at Tehran University and then started to work as a pathologist at Shahid Beheshti hospital in Iran for one year. In 2011, she furthered her studies by obtaining a Master of Science degree in molecular medicine and cancer research at Brunel University London where she studied epigenetics in Friedreich ataxia patients and mouse models. She joined Oxford Biodynamics as a research technician in 2012 and continues to work as a project manager

Matthew read Molecular Biology at the University of Exeter graduating in 2010. He joined Oxford Biodynamics in 2012 as a lab technician, gaining experience and progressing in the company. Matthew is a Prince2 qualified project manager working alongside Dr Ewan Hunter in the analytics department.